Positive topline results for faricimab for neovascular age-related macular degeneration
Both the TENAYA and LUCERNE phase III studies (pooled n= 1,329) met their primary endpoint demonstrating that faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were non-inferior to aflibercept injections every eight weeks.
Source:
Biospace Inc.